JPMorgan lowered the firm’s price target on Travere Therapeutics (TVTX) to $41 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotech space.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics
- Travere Therapeutics Earnings Call Shows Growth Amid Risks
- Travere Therapeutics: Buy Rating Anchored by Filspari’s 2026 FSGS Catalyst and Supported by IgAN Franchise Strength
- Travere Therapeutics, Inc. (TVTX) Q4 Earnings Cheat Sheet
- Travere Therapeutics price target raised to $38 from $35 at Piper Sandler